v3.24.2.u1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Jul. 31, 2024
Jul. 31, 2023
Operating expenses:    
Research and development $ 26,614 $ 19,307
General and administrative 17,601 9,786
Total operating expenses 44,215 29,093
Operating loss (44,215) (29,093)
Other income:    
Interest income 1,692 923
Foreign currency exchange gain 514 456
Other income 1,566 2,397
Total other income 3,772 3,776
Net loss (40,443) (25,317)
Other comprehensive (loss) income:    
Foreign currency translation (loss) gain (128) 91
Unrealized holding gain on marketable securities 1,064 392
Reclassification adjustment for realized (gain) loss on marketable securities included in net loss (317) (314)
Other comprehensive income 619 169
Comprehensive loss $ (39,824) $ (25,148)
Net loss per share to common stockholders, basic $ (0.87) $ (0.74)
Net loss per share to common stockholders, diluted $ (0.87) $ (0.74)
Weighted average common shares outstanding, basic 46,232,977 34,414,226
Weighted average common shares outstanding, diluted 46,232,977 34,414,226